• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

    11/14/24 5:05:20 PM ET
    $TRML
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TRML alert in real time by email
    SC 13G/A 1 ef20038683_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*



    Tourmaline Bio, Inc.
    (Name of Issuer)

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

    89157D 105
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

    ☒
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    NAMES OF REPORTING PERSONS
     
     
    Blue Owl Capital Holdings LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    1,530,401
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    1,530,401
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,530,401
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.0%(1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Calculated based on 25,642,610 shares of Common Stock outstanding as of November 1, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.


    Item 1(a).
    Name of Issuer

    Tourmaline Bio, Inc. (the “Issuer”)

    Item 1(b).
    Address of the Issuer’s Principal Executive Offices

    27 West 24th Street, Suite 702
    New York, New York 10010

    Item 2(a).
    Names of Persons Filing

    This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the “Reporting Person.”

    Item 2(b).
    Address of the Principal Business Office, or if none, Residence

    399 Park Avenue
    New York, New York 10022

    Item 2(c).
    Citizenship

    See response to Item 4 on the cover page.

    Item 2(d).
    Title of Class of Securities

    Common Stock, par value $0.0001 per share

    Item 2(e).
    CUSIP Number

    89157D 105

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):

    (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)

    Item 4.
    Ownership


    (a)
    Amount beneficially owned:
    See response to Item 9 on the cover page.

     
    (b)
    Percent of Class:
    See response to Item 11 on the cover page.

     
    (c)
    Number of shares as to which the Reporting Person has:

     
    (i)
    Sole power to vote or to direct the vote:
    See response to Item 5 on the cover page.

     
    (ii)
    Shared power to vote or to direct the vote:
    See response to Item 6 on the cover page.


     
    (iii)
    Sole power to dispose or to direct the disposition of:
    See response to Item 7 on the cover page.

     
    (iv)
    Shared power to dispose or to direct the disposition of:
    See response to Item 8 on the cover page.

    The filing of this statement shall not be deemed an admission by the Reporting Person of beneficial ownership of the reported securities for purposes of Section 13(d) or Section 13(g) or any other purpose.

    Item 5.
    Ownership of Five Percent or Less of a Class

    Not Applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not Applicable.

    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group

    Not Applicable.

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024


    BLUE OWL CAPITAL HOLDINGS LP



    By:
    /s/ Karen Hager
       
     Name:
    Karen Hager
       
     Title:
    Chief Compliance Officer



    Get the next $TRML alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRML

    DatePrice TargetRatingAnalyst
    4/23/2025$70.00Buy
    Chardan Capital Markets
    3/6/2025$42.00Outperform
    Wedbush
    12/6/2024$50.00Outperform
    BMO Capital Markets
    11/11/2024$48.00 → $49.00Buy
    H.C. Wainwright
    12/15/2023$41.00Buy
    Jefferies
    12/4/2023$48.00Buy
    H.C. Wainwright
    11/17/2023$43.00Buy
    Truist
    10/31/2023$50.00Buy
    Guggenheim
    More analyst ratings

    $TRML
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:46:12 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:05:20 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 4:32:01 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Leadership Updates

    Live Leadership Updates

    See more
    • Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). "We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of card

      1/10/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

      Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa

      4/2/24 7:00:00 AM ET
      $AVTX
      $TRML
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

      NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines

      12/14/23 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Kulkarni Sandeep Chidambar bought $26,418 worth of shares (1,779 units at $14.85) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/22/24 4:22:14 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO Kulkarni Sandeep Chidambar bought $71,998 worth of shares (5,221 units at $13.79) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/20/24 6:09:47 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Kulkarni Sandeep Chidambar

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      2/4/25 4:19:06 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Robinson Ryan F.

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:34 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CBO, GC and Secretary Middlekauff W Bradford

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:21 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Tourmaline with a new price target

      Chardan Capital Markets initiated coverage of Tourmaline with a rating of Buy and set a new price target of $70.00

      4/23/25 8:18:16 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Tourmaline with a new price target

      Wedbush initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $42.00

      3/6/25 7:32:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Tourmaline with a new price target

      BMO Capital Markets initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $50.00

      12/6/24 8:19:37 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Financials

    Live finance-specific insights

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    SEC Filings

    See more
    • Tourmaline Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/20/25 9:02:35 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tourmaline Bio Inc.

      SCHEDULE 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      5/15/25 4:22:00 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tourmaline Bio Inc.

      10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/2/25 8:12:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care